Overall, while these studies provide proof‐of‐principle of the advantageous outcome of senescence clearance therapy as an approach to mitigate cancer recurrence, future studies will also be directed toward the optimization of BCL‐2/BCL‐XL inhibitors such as navitoclax as well as the identification of less toxic senolytic agents. Here, BCL2 is linked to cancer.